COMMUNIQUÉS West-GlobeNewswire

Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
22/10/2018
Study Results Presented at a Major European Cancer Conference (ESMO) PLYMOUTH MEETING, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that new data from the company’s [...]
Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
22/10/2018
Company’s Chief Scientific Officer to Participate in “New Approaches to Combating Opioids” Panel SANTA MONICA, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a [...]
Nova Leap Health Corp. Completes Purchase of New Hampshire Home Health Care Business
22/10/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Oct. 22, 2018 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a company focused on [...]
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
22/10/2018
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY, Calif., Oct. 22, [...]
Coherus BioSciences to Report Third Quarter 2018 Financial Results on November 8th
22/10/2018
REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market close on Thursday, November 8 [...]
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
22/10/2018
Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity AUSTIN, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops [...]
Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT
22/10/2018
-- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65 th American Academy of Child and Adolescent Psychiatry (AACAP) [...]
PetMed Express D/B/A 1-800-PetMeds Announces its Second Quarter Financial Results
22/10/2018
Second Quarter Net Income Increased 23% Second Quarter Reorder Sales Increased 11% Second Quarter Diluted EPS $0.52 per share vs $0.43 per share DELRAY BEACH, Fla., Oct. 22, 2018 (GLOBE NEWSWIRE) -- PetMed Express, Inc [...]
Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments
22/10/2018
LOUGHBOROUGH, England - Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes [...]
Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer
22/10/2018
NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]
Extendicare Announces Timing of 2018 Third Quarter Results and Conference Call
22/10/2018
MARKHAM, Ontario, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the third quarter of 2018, after market [...]
Quotient Limited to Report Fiscal Second Quarter 2019 Financial Results and Host Conference Call
22/10/2018
JERSEY, Channel Islands, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30 [...]
Tabula Rasa HealthCare Announces the Launch of CareVention HealthCare
22/10/2018
New division will integrate TRHC’s offerings into one comprehensive suite of technology solutions and consulting services for healthcare organizations MOORESTOWN, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa [...]
Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors
22/10/2018
Intratumoral injections of INT230-6 were well tolerated with no drug-related serious adverse events or dose-limiting toxicity Increases in circulating CD8 and CD4 T-cells and evidence of abscopal responses in non- [...]
Repligen to Report Third Quarter 2018 Financial Results
22/10/2018
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report [...]
Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting
22/10/2018
Data presented at 2018 American College of Rheumatology (ACR) Annual Meeting show concurrent, bilateral administration of ZILRETTA appeared safe and well tolerated Systemic exposure to triamcinolone acetonide was 10- [...]
Innovation Pharmaceuticals Provides Update on Kevetrin Program; Bridging Toxicology Efforts Aimed at Developing an Oral p53 Anti-Cancer Drug Candidate
22/10/2018
BEVERLY, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update on the Company’s p53 anti [...]
Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association
22/10/2018
~ As Previously Reported, SONICS Met its Primary Endpoint With 30 Percent of the ITT Patient Population Reaching & Maintaining Mean Urinary Free Cortisol (mUFC) Normalization Following Six Months of Maintenance [...]
BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress
22/10/2018
CAMBRIDGE, Mass. and BEIJING, China, Oct. 22, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

Pages